Descrizione del progetto
Un accurato test diagnostico in vitro per la malattia meningococcica
La malattia meningococcica costituisce un grave problema di salute che colpisce milioni di persone ogni anno, per la quale tuttavia mancano test diagnostici rapidi e accurati. Per affrontare questo problema, la francese BioSpeedia ha sviluppato un test diagnostico in vitro non invasivo in grado di rilevare i diversi sierotipi del patogeno. La sensibilità, la specificità e la rapidità elevate di questo test, associate alla convenienza, offrono uno strumento diagnostico affidabile della malattia meningococcica, anche per i sistemi sanitari con risorse limitate. Il progetto MeningoSpeed, finanziato dall’UE, condurrà uno studio di fattibilità per l’ingresso sul mercato di questo test diagnostico altamente promettente che può contribuire a iniziare un trattamento tempestivo e precoce nei pazienti con malattia meningococcica, migliorando notevolmente il risultato clinico e riducendo la letalità della malattia.
Obiettivo
Meningococcal disease (MD), caused by Neisseria meningitidis serogroups (mainly ABCXWY), annually affects 1.2 million people worldwide (mainly children and young). Due to its high lethality (8-15% treated patients), permanent sequelae and epidemic potential, MD represents a major public health problem. Despite the societal burden, there is a lack of rapid and accurate diagnostic tools for timely and early treatment that results very costly for healthcare systems (e.g. direct costs valued in € 68 m/hospital/year). In response to the unmet need, BioSpeedia (spin-off from the Institute Pasteur, France) has vast experience in infectious diseases management and is developing the first-ever gold nanoparticle-based immunochromatographic test with demonstrated diagnostic capability for the six Nm serogroups. MeningoSpeed is a non-invasive, accurate (sensitivity and specificity >93%), rapid (<15 min vs PCR: 3h) and cost-competitive in vitro diagnostic test (€45 sample, at least 25 % cheaper than latex agglutination tests and PCR alternatives) for MD diagnosis. Our one-step solution will result on added value for patients, physicians and healthcare purchasers by improving disease monitoring in an accurate and timely fashion way, reducing deaths and sequelae. MeningoSpeed will provide healthcare systems with limited resources with a reliable and cost-effective diagnostic tool, leading to significant cost-savings. MeningoSpeed´s high accuracy and performance under a faster and cheaper cost make it a disruptive solution with great potential for commercial success in the growing point-of-care market (€33 B by 2022, CAGR 10%). Thus, MeningoSpeed is projected to be a profitable business opportunity and a core source of growth for the company (ca. €33 M of accumulated net profit during 2022-2026). A next feasibility study covering the technological, commercial and financial issues will enable us to finalize our business plan and secure our steps towards the successful market launch.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
75724 PARIS
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.